Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 2/20 | 0.61 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1635068 | 0.90 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL1635889 | 0.88 | PDE4A (0.62) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL8178988 | 0.87 | PDE4A (0.71) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL1634917 | 0.87 | NPC1 (0.58) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL6138174 | 0.79 | HTT (0.61) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL31465194 | 0.79 | HTT (0.61) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL15572275 | 0.78 | TSHR (0.67) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL15968774 | 0.78 | PDE4A (0.60) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL17545334 | 0.77 | PDE4A (0.59) | PDE4APDE4BPDE4CPDE4DKMT2A | |
| SCHEMBL1636167 | 0.77 | PDE4A (0.53) | PDE4APDE4BPDE4CPDE4DKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932242-B2 | Anticancer agents; radiation and chemical resistance | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-04-26 | — | — | US | disclosed |
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2008-03-06 | — | — | US | disclosed |
| EP-1740530-A4 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | UNIV TEMPLE (US) | 2008-02-27 | — | — | EP | disclosed |
| EP-1740530-A2 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | Temple University of the Commonwealth System of Higher Education (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005089269-A2 | SUBSTITUTED PHENOXY- AND PHENYLTHIO- DERIVATIVES FOR TREATING PROLIFERATIVE DISORDERS | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058290-A1 | Substituted Phenoxy-and Phenylthio-Derivatives for Treating Proliferative Disorders | PCNA, MKI67, TP53 | PDE4A 4197/4885PDE4B 4316/4885PDE4C 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.